Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société 4D MOLECULAR THERAPEUTICS, INC.
10/134D MOLECULAR THERAPEUTICS INC. : Other Events (form 8-K)
AQ
10/104D MOLECULAR THERAPEUTICS : ASRS 2021 Annual Meeting – 4D-125 for XLRP Phase 1/2 Cli..
PU
10/104D MOLECULAR THERAPEUTICS : Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cli..
AQ
10/064D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-710, an A101..
AQ
10/064D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-150, a Dual-..
AQ
10/04CHOROIDEREMIA PIPELINE : Industry Analysis, Drugs, Pipeline, Treatment and Key Companies b..
AQ
09/294D MOLECULAR THERAPEUTICS : to Participate in Chardan's 5th Annual Genetic Medicines Confe..
AQ
09/244D MOLECULAR THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Stat..
AQ
09/244D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data ..
GL
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
PU
08/124D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
08/124D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial ..
AQ
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
AQ
06/254D MOLECULAR THERAPEUTICS INC. : Termination of a Material Definitive Agreement, Other Eve..
AQ
06/254D-110 : Initial clinical safety data at both of the two dose levels in the Phase 1 clinic..
PU
06/244D MOLECULAR THERAPEUTICS : Announces Rare Disease Ophthalmology Product Candidate Portfol..
AQ
06/08CHOROIDEREMIA PIPELINE : Emerging Therapies and Key pharma players involved by DelveInsigh..
AQ
06/074D MOLECULAR THERAPEUTICS : Appoints Carolyne Zimmermann as Chief Business Officer
AQ
06/034D MOLECULAR THERAPEUTICS : to Participate in Goldman Sachs 42nd Annual Global Healthcare ..
AQ
05/204D MOLECULAR THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form..
AQ
05/134D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
05/134D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial ..
AQ
05/134D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and P..
GL
05/124D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4..
GL
05/044D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technolog..
GL
04/304D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Co..
GL
04/274D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Ann..
GL
03/254D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
03/254D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial ..
AQ
03/254D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 202..
GL
03/094D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
GL
20204D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercis..
GL